Concurrent-adjuvant chemoradiotherapy for Stage III-IVB Nasopharyngeal Carcinoma – exploration for achieving optimal 10-year therapeutic ratio

Long-term outcome from 2 randomized trials confirmed that the addition of concurrent-adjuvant chemotherapy significantly improved the overall survival and disease control in advanced locoregional nasopharyngeal carcinoma without incurring significant increase in late toxicities or non-cancer deaths. The best therapeutic ratio could be achieved by 2 cycles of concurrent cisplatin plus 2-3 cycles of adjuvant cisplatin and fluorouracil.

https://ift.tt/2jncTUV